27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Amyris (NASDAQ:AMRS) shares are trading higher on Monday after the company signed a binding term sheet for a planned COVID-19 RNA vaccine technology program with the Infectious Disease Research Institute.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Amyris is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of products in a variety of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products and fuels. The company generates revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services.
Amyris shares were up 10.21% at $4.70 during the time of publication on Monday. The stock has a 52-week range between $6.07 and $1.40.